Actinium Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.38 | -$0.38 | -$0.38 |
| Q2 2024 | 1 | -$0.41 | -$0.41 | -$0.41 |
| Q3 2024 | 1 | -$0.39 | -$0.39 | -$0.39 |
| Q4 2024 | 1 | -$0.39 | -$0.29 | -$0.35 |
| Q1 2025 | 1 | -$0.34 | -$0.34 | -$0.34 |
| Q2 2025 | 1 | $0.61 | $0.61 | $0.61 |
| Q3 2025 | 1 | -$0.31 | -$0.31 | -$0.31 |
| Q4 2025 | 1 | -$0.26 | -$0.26 | -$0.26 |
Actinium Pharmaceuticals, Inc. Earnings Date And Information
Actinium Pharmaceuticals, Inc. last posted its earnings results on Monday, August 5th, 2024. The company reported $-0.38 earnings per share for the quarter, topping analysts' consensus estimates of $-0.48 by $0.1. The company had revenue of 0 for the quarter and had revenue of 81,000 for the year. Actinium Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.83 diluted earnings per share) and currently has a price-to-earnings ratio of -1.08. Actinium Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 14th, 2025 based on prior year's report dates.
Actinium Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.37 | $0 | $0 | ||
| 08/05/2024 | Q2 2024 | -$0.48 | -$0.38 | 0.1 | $5.10 M | $0 |
| 04/26/2024 | Q1 2024 | -$0.42 | -$0.31 | 0.11 | $0 | |
| 03/29/2024 | Q4 2023 | -$0.54 | -$0.34 | 0.2 | $81,000 | |
| 11/02/2023 | Q3 2023 | -$0.53 | -$0.49 | 0.04 | $575,000 | $0 |
| 08/14/2023 | Q2 2023 | -$0.50 | -$0.58 | -0.08 | $0 | |
| 05/15/2023 | Q1 2023 | -$0.42 | -$0.41 | 0.01 | $0 | |
| 03/31/2023 | Q4 2022 | -$0.39 | $114,000 | |||
| 11/14/2022 | Q3 2022 | -$0.30 | -$0.37 | -0.07 | $580,000 | $45,000 |
| 08/12/2022 | Q2 2022 | -$0.23 | -$0.33 | -0.1 | $12.28 M | $45,000 |
| 05/13/2022 | Q1 2022 | -$0.31 | -$0.23 | 0.08 | $940,000 | |
| 03/25/2022 | Q4 2021 | -$0.30 | -$0.37 | -0.07 | $23,000 | |
| 11/12/2021 | Q3 2021 | -$0.29 | -$0.30 | -0.01 | $70,000 | $233,000 |
| 07/30/2021 | Q2 2021 | -$0.30 | -$0.25 | 0.05 | $133,000 | $266,000 |
| 05/14/2021 | Q1 2021 | -$0.29 | -$0.29 | 0 | $622,000 | |
| 03/31/2021 | Q4 2020 | -$0.37 | -$0.35 | 0.02 | $0 | |
| 10/23/2020 | Q3 2020 | -$0.44 | -$0.36 | 0.08 | $0 | |
| 08/14/2020 | Q2 2020 | -$0.40 | -$0.41 | -0.01 | $0 | |
| 06/29/2020 | Q1 2020 | -$0.98 | $0 | |||
| 05/08/2020 | Q4 2019 | -$0.84 | $0 |
Actinium Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Actinium Pharmaceuticals, Inc.'s earnings date?
Actinium Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 14th, 2025 based off last year's report dates.
-
Did Actinium Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Actinium Pharmaceuticals, Inc. (:ATNM) reported $-0.38 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.48 by $0.1.
-
How can I listen to Actinium Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Actinium Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Actinium Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Actinium Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Actinium Pharmaceuticals, Inc. generate each year?
Actinium Pharmaceuticals, Inc. (:ATNM) has a recorded annual revenue of $81,000.
-
How much profit does Actinium Pharmaceuticals, Inc. generate each year?
Actinium Pharmaceuticals, Inc. (:ATNM) has a recorded net income of $81,000. Actinium Pharmaceuticals, Inc. has generated $-1.83 earnings per share over the last four quarters.
-
What is Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio?
Actinium Pharmaceuticals, Inc. (:ATNM) has a price-to-earnings ratio of -1.08 and price/earnings-to-growth ratio is -0.14.
